Debra Aub Webster is a senior regulatory affairs leader with more than 30 years’ experience across biotech, advanced therapeutics, consulting, government, and academia. She has held global leadership roles shaping regulatory strategy for drugs, biologics, and cell and gene therapies, including senior positions at SSI Strategy, Aditum Bio, BlueRock Therapeutics, and Cardinal Health. Debra is recognized for guiding complex programs from preclinical development through regulatory approval, leading global health authority interactions, and building high-performing regulatory and medical writing teams. Her work emphasizes risk-based strategy, cross-functional alignment, and accelerating innovative therapies to patients.

Ingela Loell is a seasoned scientific editor and writer with extensive experience producing high-quality scientific content aligned with organizational objectives. She brings a strong track record in managing content pipelines, meeting defined volume targets, and maintaining rigorous editorial quality and style compliance. Her work spans strategic content planning, including inventory management and gap analysis, to ensure alignment with corporate focus areas. Ingela collaborates closely with cross-functional stakeholders and serves as a coordinating liaison across multiple Centers of Excellence, supporting knowledge dissemination, measurable deliverables, and timely project execution within complex organizational environments.